Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has achieved alignment with the United States Food and Drug Administration (FDA) Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 clinical trials to evaluate batoclimab in TED. Immunovant expects to initiate its Phase 3 TED program in the second half of calendar year 2022.

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will report its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, June 8, 2022. The company also plans to host a webcast and conference call on Wednesday, June 8, 2022 at 8:00 AM ET.

Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, taking place May 23rd-26th, 2022.

Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference, taking place May 23rd-25th, 2022.

Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

Event will feature six key opinion leaders with expertise in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol management Event will feature six key opinion leaders with expertise in thyroid eye disease, myasthenia gravis, warm autoimmune hemolytic anemia, and cholesterol management

Immunovant to Host Virtual R&D Day on March 30, 2022

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022.

Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3

Plans to initiate phase 3 study using batoclimab for the treatment of patients with myasthenia gravis expected 1st half of 2022.

Immunovant: Speculative Biotech With Proven Class Of Drugs Targeting FcRn Pathway

Company Ended the Quarter With Cash of Approximately $527.0 Million Company Ended the Quarter With Cash of Approximately $527.0 Million

Immunovant Reports Financial Results for the Quarter Ended December 31, 2021

NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer.

Immunovant Appoints Mark Levine as Chief Legal Officer

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 - 13, 2022.

Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced that the Company achieved alignment with the FDA Division of Neurology 1 (“FDA”) to move forward in myasthenia gravis (“MG”). Immunovant plans to start its Phase 3 study for batoclimab in MG in the first half of calendar year 2022.

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021.

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2

Company Ended the Quarter With Cash of Approximately $559 Million Company Ended the Quarter With Cash of Approximately $559 Million

Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R&D Day 2021 on Tuesday, September 28, 2021 at 4:00 p.m. ET.

Immunovant to Participate in Roivant R&D Day 2021

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?

Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?

Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1

Immunovant, Inc. (IMVT) CEO Pete Salzmann on Q1 2022 Results - Earnings Call Transcript

Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant

Immunovant Reports Financial Results for the Quarter Ended June 30, 2021

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will host a conference call and audio webcast on Monday, August 9, 2021 at 8 a.m. ET to discuss financial results for its fiscal first quarter ended June 30, 2021.

Immunovant to Report Financial Results for Quarter Ended June 30, 2021

An analyst note is extending yesterday's sell-off.

Why Shares of Immunovant Are Down Almost 10% This Afternoon

Drugmaker Roviant Sciences had been plotting a novel take on the popular SPAC deal, according to a report from Bloomberg.

SPAC engineering reaches new heights as scrapped deal sends pharma firm's stock plunging 36%

Shareholders are throwing in the towel after not getting the deal they were expecting.

Why Shares of Immunovant Are Tanking Today

Credit Suisse downgraded Immunovant Inc (NASDAQ:IMVT) to Underperform from Neutral and lowered the price target to $7 from $12.  Analyst Tiago Fauth says that the downgrade reflects ongoing clinical and regulatory uncertainties for IMVT-1401 owing to safety concerns, likely extended clinical timelines with no clear value-driving catalysts in the next 12-months.

News for Immunovant Inc Stock (IMVT)